Furthermore, responders to anti-PD1 immunotherapy showed lower methylation levels (Figure 12C), and in different silencing score groups (high vs low), the patients exhibited significant differences in immune response (Non-response vs. response) (Figures 12D, p = 0.003). These data suggest that DNA hypomethylation of LRRC3B could be used to predict anti-PD-1 treatment outcomes in NSCLC and BRCA.